Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action.
Journal: Antiviral research
Published: November 22, 2022
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Journal: PloS one
Published: September 01, 2019
Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
Journal: Infectious disorders drug targets
Published: April 21, 2014
Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa.
Journal: Antiviral research
Published: February 03, 2014
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
Journal: Expert review of anti-infective therapy
Published: December 20, 2013
Discordant biological and toxicological species responses to TLR3 activation.
Journal: The American journal of pathology
Published: August 19, 2013
Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Published: December 03, 2011
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
Journal: PloS one
Published: June 25, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026